Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.1105 | 1 | 1 |
Toxoplasma gondii | PAN domain-containing protein | 0.1065 | 0.9489 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0368 | 0.0672 | 0.061 |
Plasmodium vivax | cysteine repeat modular protein 1, putative | 0.0368 | 0.0672 | 0.5 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.1105 | 1 | 1 |
Onchocerca volvulus | 0.1105 | 1 | 1 | |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0368 | 0.0672 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1105 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0368 | 0.0672 | 0.5 |
Loa Loa (eye worm) | TK/ROR protein kinase | 0.0368 | 0.0672 | 0.061 |
Echinococcus multilocularis | tissue type plasminogen activator | 0.0368 | 0.0672 | 1 |
Plasmodium falciparum | cysteine repeat modular protein 1 | 0.0368 | 0.0672 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0368 | 0.0672 | 0.0672 |
Echinococcus granulosus | tissue type plasminogen activator | 0.0368 | 0.0672 | 1 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.1105 | 1 | 1 |
Onchocerca volvulus | 0.0879 | 0.7135 | 0.6929 | |
Toxoplasma gondii | PAN domain-containing protein | 0.1065 | 0.9489 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | > 30 uM | Inhibitory activity against interleukin-8 receptor using [125I]-IL8 | ChEMBL. | No reference |
Ki (binding) | > 30 uM | Inhibitory activity against interleukin-8 receptor using [125I]-IL8 | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.